Modifications

Aller à la navigation Aller à la recherche
1 011 octets ajoutés ,  26 août 2015 à 16:08
aucun résumé des modifications
Ligne 1 : Ligne 1 : −
[[image:Marco_Ruggiero.jpg|Marco Ruggiero Source le site d'AutismOne<ref>http://www.autismone.org/users/marco-ruggiero</ref>|400px|thumb]]
+
[[image:Marco_Ruggiero.jpg|Marco Ruggiero Source le site d'AutismOne<ref name='autismone'>http://www.autismone.org/users/marco-ruggiero</ref>|400px|thumb]]
'''Marco Ruggiero''', né le 19 janvier 1956 à Florence (Italie], est titulaire d'un doctorat en biologie moléculaire, médecin spécialisé en radiologie clinique. Il a été professeur de biologie moléculaire au Département de expérimentale et clinique de sciences biomédicales de l'Université de Firenze (Italie) depuis plus de 20 ans (1992-2014). Depuis 2013, il est Directeur scientifique à Immuno Biotech Ltd, à Guernesey, Iles Anglo-Normandes, Grande-Bretagne<ref>http://www.autismone.org/users/marco-ruggiero</ref> dont le directeur est [[David Noakes]].
+
'''Marco Ruggiero''', né le 19 janvier 1956 à Florence (Italie], est titulaire d'un doctorat en biologie moléculaire, médecin spécialisé en radiologie clinique. Il a été professeur de biologie moléculaire au Département de expérimentale et clinique de sciences biomédicales de l'Université de Firenze (Italie) depuis plus de 20 ans (1992-2014). Depuis le 1er novembre 2013, il est consultant-scientific-director (directeur scientifique consultant<ref>http://www.firstimmune.it/professor-marco-ruggiero-md-joins-us-on-the-1st-november-as-consultant-scientific-director/</ref>d'Immuno Biotech Ltd, à Guernesey, Iles Anglo-Normandes, Grande-Bretagne<ref name='autismone'></ref> dont le directeur est [[David Noakes]].
    
== Négationiste du VIH ==
 
== Négationiste du VIH ==
Ligne 12 : Ligne 12 :     
== Le probiotique Bravo additionné de GcMAF de Ruggiero==
 
== Le probiotique Bravo additionné de GcMAF de Ruggiero==
<ref>http://firenze.repubblica.it/cronaca/2015/05/16/news/medico_nego_l_aids_ora_vende_yogurt_anti-cancro_-114526984/ Article publié le 16 mai 2015</ref>
+
Article "Le docteur qui nie le SIDA vend maintenant du yaourt anti-cancer", par Gerardo Adinolfi, publié le 16 mai 2015 <ref>http://firenze.repubblica.it/cronaca/2015/05/16/news/medico_nego_l_aids_ora_vende_yogurt_anti-cancro_-114526984/ Article publié le 16 mai 2015</ref>.
 +
 
 
<ref>http://www.firstimmune.fr/gcmaf-products/bravo-probiotic/&usg=ALkJrhgxHDbl09RRRP6bPpkpJTztUSERsg le probiotique Bravo sur le site de First Immune</ref>
 
<ref>http://www.firstimmune.fr/gcmaf-products/bravo-probiotic/&usg=ALkJrhgxHDbl09RRRP6bPpkpJTztUSERsg le probiotique Bravo sur le site de First Immune</ref>
<ref>http://www.moneyhouse.ch/it/u/silver_spring_sagl_CH-501.4.019.701-7.htm&usg=ALkJrhg1vd7Jn43hI4QUERvZ8nyroO8jTg Silver Spring Sagl, c/o Fulvia Gianetta Allio, Via Raimondo Rossi 24, 6864 Arzo, appartenant à Marco Ruggiero</ref>
+
 
 +
La Sarl Silver Spring <ref>http://www.moneyhouse.ch/it/u/cv_CH-501.4.019.701-7.htm&usg=ALkJrhg1vd7Jn43hI4QUERvZ8nyroO8jTg Le 9 février 2012, la Silver Spring Sagl (Sagl=Sarl), c/o Fulvia Gianetta Allio, Via Raimondo Rossi 24, 6864 Arzo, est créée par  Marco Ruggiero.</ref> est le lieu de contact pour commander sur le site marchand bravo-europe.com<ref>https://www.bravo-europe.com/ Cliquez sur "contact us"</ref>, ce site propose le "bravo easy kit", une yaoutière, pour la modeste somme de 400€ https://www.bravo-europe.com/shop/uncategorized/bravo-easy-kit/</ref>.
    
== Liens externes ==
 
== Liens externes ==
 
* http://scholarlyoa.com/2014/07/24/would-you-take-a-cancer-cure-proven-effective-in-a-predatory-journal/<br>I am writing this blog post in hopes of starting a conversation in the scientific community about the medicine called [[GcMAF]] and one of the companies that is currently distributing it, a company called GcMAF.eu<br><br>[[GcMAF]] means “Gc protein-derived macrophage activating factor,” according to the short article about it on Wikipedia. The drug is currently being marketed as a cure for many ailments, including cancer, autism, MS and Parkinson’s disease.<br><br>I am concerned about this drug and its marketing for these reasons:<br>1. Apparently, some of the same people who are researching the drug also are involved in marketing and selling it.<br>2. Some (not all) of their research has been published in questionable journals, including one published by a publisher that is on my list.<br>3. The drug is not approved by any competent authority (FDA, EMA) to treat any disease.<br><br>The following three articles report favorably on [[GcMAF]] and appear in the American Journal of Immunology a journal published by Science Publications, a publisher on my list. The three articles are:<br>1.Thyer, L., Ward, E., Smith, R., Branca, J. J. V., Morucci, G., Gulisano, M., [[David Noakes|Noakes, D.]] & Pacini, S. (2013). Therapeutic effects of highly purified de-glycosylated [[GcMAF]] in the immunotherapy of patients with chronic diseases. American Journal of Immunology, 9(3), 78-84.<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738989/ Article "Therapeutic effects of highly purified de-glycosylated [[GcMAF]] in the immunotherapy of patients with chronic diseases"</ref><br>2.Smith, R., Thyer, L., Ward, E., Meacci, E., Branca, J. J. V., Morucci, G., Gulisano, M. R., Ruggiero, M., Pacini, A, Paternostro, F., Di Cesare Mannelli, L., [[David Noakes|Noakes, D. J.]], & Pacini, S. (2013). Effects of Gc-macrophage activating factor in human neurons; implications for treatment of chronic fatigue syndrome. American Journal of Immunology, 9(4), 120-129.<ref>http://thescipub.com/PDF/ajisp.2013.120.129.pdf Article "Effects of Gc-macrophage activating factor in human neurons; implications for treatment of chronic fatigue syndrome"</ref><br>3.Ward, E., Smith, R., Branca, J. J. V., [[David Noakes|Noakes, D.]], Morucci, G., & Thyer, L. (2014). Clinical Experience of Cancer Immunotherapy Integrated with Oleic Acid Complexed with De-Glycosylated Vitamin D Binding Protein. American Journal of Immunology, 10(1), 23-32.<ref>http://www.legamberifoods.com/polopoly_fs/1.155809.1411607941!/httpFile/file.pdf Article "Clinical Experience of Cancer Immunotherapy Integrated with Oleic Acid Complexed with De-Glycosylated Vitamin D Binding Protein"</ref><br><br>The first and the third articles report the authors’ experience with patients treated at the Immuno Biotech Treatment Center. From their website one sees that the cost is €6,000 a week for the center, and their hotel cost estimate is €1,800. This price is significantly higher than the €600 they charge for the [[GcMAF]] ampule alone. These patients have been an important source of revenue for this company.<br><br>As far as I can tell, none of the authors discloses affiliation to this center, so it is not clear who treated the patients. Moreover, there is no other information on this treatment center than the information on these articles and the website of this company. Thus it is rather strange that patients have to have a separate budget for their accommodation, which means there are being treated as outpatients. What is the point on making them travel to receive a treatment that could be given on an outpatient basis by one of the 350 doctors around the world claimed to be using [[GcMAF]]?<br><br>The publisher of the journal, Science Publications, lists two addresses on its “Contact Us” page, one in Adelaide, SA, Australia and one in New York, NY, USA. I think both addresses are really those of mail-forwarding services and the publisher is hiding its true location, which remains unknown.<br><br>Why are these scientists publishing their work in a highly questionable journal operated by a non-transparent publisher? If the work is so groundbreaking (a cure for cancer, et al.), why not publish it in a legitimate journal where its impact would be greater, its conclusions more convincing?<br><br>Do any of the authors have any declarable conflicts of interest? If so, what are they? Where can I find them?<br><br>On the [[GcMAF]].eu website, the site of the company that sells the potion, under the “Who we are” link, it says this:<br><br>We are a group of scientists led by Professor Marco Ruggiero MD, a molecular biologist and fully qualified medical doctor. The team includes a PhD and two BSc biomedical scientists. External doctors, oncologists and scientists kindly provide help and advice. We are committed to bringing [[GcMAF]] and its associated treatments to as many people as we can.<br><br>Ruggiero is listed as one of the authors of one of the articles above, so I assume the other authors are part of his team and are associated with the company [[GcMAF]].eu.<br><br>One of the first scientists to research [[GcMAF]] was Nobuto Yamamoto, but his 2007 article on the compound was retracted.<br><br>Regarding pricing, the company’s website states<br><br>Our GcMAF is €600, plus €60 packing and shipping, for one 2.2ml vial. A vial is one third full and contains up to eight doses – one 100ng, 0.25ml dose a week.<br><br>I found the overall tone of the GcMAF website to be mean and self-righteous. It makes a lot of claims such as “Root canals are a major cause of the immune system being suppressed and they are a major cause of cancer.”<br><br>Is the published science behind [[GcMAF]] authentic, honest, and real? I ask that the bio-medical sciences community investigate this compound, the science behind it, and its marketing.<br><br>Coda: A good analysis of GcMAF is available from the Anticancer Fund here.<br><br>
 
* http://scholarlyoa.com/2014/07/24/would-you-take-a-cancer-cure-proven-effective-in-a-predatory-journal/<br>I am writing this blog post in hopes of starting a conversation in the scientific community about the medicine called [[GcMAF]] and one of the companies that is currently distributing it, a company called GcMAF.eu<br><br>[[GcMAF]] means “Gc protein-derived macrophage activating factor,” according to the short article about it on Wikipedia. The drug is currently being marketed as a cure for many ailments, including cancer, autism, MS and Parkinson’s disease.<br><br>I am concerned about this drug and its marketing for these reasons:<br>1. Apparently, some of the same people who are researching the drug also are involved in marketing and selling it.<br>2. Some (not all) of their research has been published in questionable journals, including one published by a publisher that is on my list.<br>3. The drug is not approved by any competent authority (FDA, EMA) to treat any disease.<br><br>The following three articles report favorably on [[GcMAF]] and appear in the American Journal of Immunology a journal published by Science Publications, a publisher on my list. The three articles are:<br>1.Thyer, L., Ward, E., Smith, R., Branca, J. J. V., Morucci, G., Gulisano, M., [[David Noakes|Noakes, D.]] & Pacini, S. (2013). Therapeutic effects of highly purified de-glycosylated [[GcMAF]] in the immunotherapy of patients with chronic diseases. American Journal of Immunology, 9(3), 78-84.<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738989/ Article "Therapeutic effects of highly purified de-glycosylated [[GcMAF]] in the immunotherapy of patients with chronic diseases"</ref><br>2.Smith, R., Thyer, L., Ward, E., Meacci, E., Branca, J. J. V., Morucci, G., Gulisano, M. R., Ruggiero, M., Pacini, A, Paternostro, F., Di Cesare Mannelli, L., [[David Noakes|Noakes, D. J.]], & Pacini, S. (2013). Effects of Gc-macrophage activating factor in human neurons; implications for treatment of chronic fatigue syndrome. American Journal of Immunology, 9(4), 120-129.<ref>http://thescipub.com/PDF/ajisp.2013.120.129.pdf Article "Effects of Gc-macrophage activating factor in human neurons; implications for treatment of chronic fatigue syndrome"</ref><br>3.Ward, E., Smith, R., Branca, J. J. V., [[David Noakes|Noakes, D.]], Morucci, G., & Thyer, L. (2014). Clinical Experience of Cancer Immunotherapy Integrated with Oleic Acid Complexed with De-Glycosylated Vitamin D Binding Protein. American Journal of Immunology, 10(1), 23-32.<ref>http://www.legamberifoods.com/polopoly_fs/1.155809.1411607941!/httpFile/file.pdf Article "Clinical Experience of Cancer Immunotherapy Integrated with Oleic Acid Complexed with De-Glycosylated Vitamin D Binding Protein"</ref><br><br>The first and the third articles report the authors’ experience with patients treated at the Immuno Biotech Treatment Center. From their website one sees that the cost is €6,000 a week for the center, and their hotel cost estimate is €1,800. This price is significantly higher than the €600 they charge for the [[GcMAF]] ampule alone. These patients have been an important source of revenue for this company.<br><br>As far as I can tell, none of the authors discloses affiliation to this center, so it is not clear who treated the patients. Moreover, there is no other information on this treatment center than the information on these articles and the website of this company. Thus it is rather strange that patients have to have a separate budget for their accommodation, which means there are being treated as outpatients. What is the point on making them travel to receive a treatment that could be given on an outpatient basis by one of the 350 doctors around the world claimed to be using [[GcMAF]]?<br><br>The publisher of the journal, Science Publications, lists two addresses on its “Contact Us” page, one in Adelaide, SA, Australia and one in New York, NY, USA. I think both addresses are really those of mail-forwarding services and the publisher is hiding its true location, which remains unknown.<br><br>Why are these scientists publishing their work in a highly questionable journal operated by a non-transparent publisher? If the work is so groundbreaking (a cure for cancer, et al.), why not publish it in a legitimate journal where its impact would be greater, its conclusions more convincing?<br><br>Do any of the authors have any declarable conflicts of interest? If so, what are they? Where can I find them?<br><br>On the [[GcMAF]].eu website, the site of the company that sells the potion, under the “Who we are” link, it says this:<br><br>We are a group of scientists led by Professor Marco Ruggiero MD, a molecular biologist and fully qualified medical doctor. The team includes a PhD and two BSc biomedical scientists. External doctors, oncologists and scientists kindly provide help and advice. We are committed to bringing [[GcMAF]] and its associated treatments to as many people as we can.<br><br>Ruggiero is listed as one of the authors of one of the articles above, so I assume the other authors are part of his team and are associated with the company [[GcMAF]].eu.<br><br>One of the first scientists to research [[GcMAF]] was Nobuto Yamamoto, but his 2007 article on the compound was retracted.<br><br>Regarding pricing, the company’s website states<br><br>Our GcMAF is €600, plus €60 packing and shipping, for one 2.2ml vial. A vial is one third full and contains up to eight doses – one 100ng, 0.25ml dose a week.<br><br>I found the overall tone of the GcMAF website to be mean and self-righteous. It makes a lot of claims such as “Root canals are a major cause of the immune system being suppressed and they are a major cause of cancer.”<br><br>Is the published science behind [[GcMAF]] authentic, honest, and real? I ask that the bio-medical sciences community investigate this compound, the science behind it, and its marketing.<br><br>Coda: A good analysis of GcMAF is available from the Anticancer Fund here.<br><br>
 
* http://www.anticancerfund.org/fr/news/gcmaf-for-the-treatment-of-breast-cancer-retraction-of-an-article-by-yamamoto-et-al Rétraction d'un article de Yamamto et al. concernant le [[GcMAF]] en tant que traitement du cancer du sein
 
* http://www.anticancerfund.org/fr/news/gcmaf-for-the-treatment-of-breast-cancer-retraction-of-an-article-by-yamamoto-et-al Rétraction d'un article de Yamamto et al. concernant le [[GcMAF]] en tant que traitement du cancer du sein
 +
* http://journal.frontiersin.org/article/10.3389/fnhum.2013.00934/abstract Papier "A new methodology of viewing extra-axial fluid and cortical abnormalities in children with autism via transcranial ultrasonography", auteurs : James Jeffrey Bradstreet, Stefania Pacini and Marco Ruggiero, publié le 15 janvier 2014 dans la revue Frontiers in Human Neuroscience.
    
[[image:Healing_Autism_Rivera_Ruggiero.jpg|400px|thumb]]
 
[[image:Healing_Autism_Rivera_Ruggiero.jpg|400px|thumb]]
Ligne 29 : Ligne 32 :  
[[category:Médecin]]
 
[[category:Médecin]]
 
[[category:Dénialiste du VIH]]
 
[[category:Dénialiste du VIH]]
[[category:Charlatan]]
+
[[category:Pseudo-thérapeute]]
12 795

modifications

Menu de navigation